Etanercept-induced necrotizing crescentic glomerulonephritis in two patients with rheumatoid arthritis

Modern Rheumatology

Volumn 20, Issue 6, 2010, Pages 632-636

  Kaneko, Kayoko ^a   Nanki, Toshihiro ^a   Hosoya, Tadashi ^a   Mizoguchi, Fumitaka ^a   Miyasaka, Nobuyuki ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Antitumor necrosis factor therapy; Etanercept; Necrotizing crescentic glomerulonephritis; Rheumatoid arthritis

Indexed keywords

ALLOPURINOL; AMLODIPINE BESYLATE; BUCILLAMINE; CREATININE; ETANERCEPT; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; TOCILIZUMAB;

ADULT; ANURIA; ARTICLE; CAPILLARY PROLIFERATION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLOMERULOSCLEROSIS; HEMATURIA; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY DISEASE; OLIGURIA; PERIPHERAL EDEMA; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; RHEUMATOID ARTHRITIS; THORAX RADIOGRAPHY; URINALYSIS;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; GLOMERULONEPHRITIS; HEMATURIA; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; NECROSIS; PROTEINURIA; RECEPTORS, TUMOR NECROSIS FACTOR; RENAL INSUFFICIENCY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650513548     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-010-0333-3     Document Type: Article

References (20)

1. T Bongartz A Sutton MJ Sweeting I• Buchan EL Matteson V Montori 2006 Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials JAMA 295 2275 2285 1:CAS:528: DC%2BD28Xksl2ktrk%3D 16705109 10.1001/jama.295.19.2275 (Pubitemid 43736578)
2. Ehrenreich T, Churg J. Pathology of membranous nephropathy. In: Sommers SC, editor. Pathology annual. New York: Appleton-Century-Crofts; 1968. p. 145-86.
3. Schwartz MM. Membranous glomerulonephritis. In: Jennette JC, Olson JL, Schwartz MM, Fred G, editors. Heptinstall's pathology of the kidney. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 205-52.
4. T Messiaen P M'bappé JJ Boffa R Khayat B Mougenot J Rossert, et al. 1998 MPO-ANCA necrotizing glomerulonephritis related to rheumatoid arthritis Am J Kidney Dis 32 E6 1:STN:280:DyaK1M7nsFCitw%3D%3D 10074594 10.1016/S0272-6386(98)70153-2
5. M Qarni DE Kohan 2000 Pauci-immune necrotizing glomerulonephritis complicating rheumatoid arthritis Clin Nephrol 54 54 58 1:STN:280: DC%2BD3M%2FlvVylsw%3D%3D 10939757 (Pubitemid 30456805)
6. M Obayashi T Uzu T Harada M Yamato K Takahara A Yamauchi 2003 Clinical course of bucillamine-induced nephropathy in patients with rheumatoid arthritis Clin Exp Nephrol 7 275 278 1:CAS:528:DC%2BD2cXlsVClsw%3D%3D 14712356 10.1007/s10157-003-0252-0 (Pubitemid 38031288)
7. A Yoshida K Morozumi T Suganuma K Sugito M Ikeda T Oikawa, et al. 1991 Clinicopathological findings of bucillamine-induced nephrotic syndrome in patients with rheumatoid arthritis Am J Nephrol 11 284 288 1:STN:280: DyaK387ovFSmsA%3D%3D 1799186 10.1159/000168323
8. T Törnroth B Skrifvars 1975 The development and resolution of glomerular basement membrane changes associated with subepithelial immune deposits Am J Pathol 79 219 236 1096633
9. SH Nasr SM Said AM Valeri MB Stokes NN Masani VD D'Agati, et al. 2009 Membranous glomerulonephritis with ANCA-associated necrotizing and crescentic glomerulonephritis Clin J Am Soc Nephrol 4 299 308 1:CAS:528: DC%2BD1MXjslagtbk%3D 19158367 10.2215/CJN.04060808
10. Y Taniguchi N Yorioka J Kumagai T Ito M Yamakido T Taguchi 1999 Myeloperoxidase antineutrophil cytoplasmic antibody-positive necrotizing crescentic glomerulonephritis and membranous glomerulonephropathy Clin Nephrol 52 253 255 1:CAS:528:DyaK1MXmsVKiurg%3D 10543328 (Pubitemid 29467101)
11. K Kanahara N Yorioka C Nakamura Y Kyuden S Ogata T Taguchi, et al. 1997 Myeloperoxidase-antineutrophil cytoplasmic antibody-associated glomerulonephritis with membranous nephropathy in remission Intern Med 36 841 846 1:STN:280:DyaK1c%2Flt1amtA%3D%3D 9392363 10.2169/internalmedicine.36.841 (Pubitemid 128521698)
12. TW Doulton B Tucker J Reardon N Velasco 2004 Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis Clin Nephrol 62 234 238 1:STN:280:DC%2BD2crht1Wgtg%3D%3D 15481857 (Pubitemid 39236628)
13. MB Stokes K Foster GS Markowitz F Ebrahimi W Hines D Kaufman, et al. 2005 Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis Nephrol Dial Transplant 20 1400 1406 1:CAS:528:DC%2BD2MXpt1Cjs7g%3D 15840673 10.1093/ndt/gfh832 (Pubitemid 41430613)
14. E Kemp H Nielsen LJ Petersen AN Gam J Dahlager T Horn, et al. 2001 Newer immunomodulating drugs in rheumatoid arthritis may precipitate glomerulonephritis Clin Nephrol 55 87 88 1:STN:280:DC%2BD3M7lsVCnsA%3D%3D 11200876 (Pubitemid 32041790)
15. D Ashok S Dubey I Tomlinson 2008 C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab Clin Rheumatol 27 261 264 17712519 10.1007/s10067-007-0712-0
16. R Simms D Kipgen S Dahill D Marshall RS Rodger 2008 ANCA-associated renal vasculitis following anti-tumor necrosis factor alpha therapy Am J Kidney Dis 51 e11 e14 18295046 10.1053/j.ajkd.2007.10.043 (Pubitemid 351273474)
17. M Ramos-Casals P Brito-Zerón S Muñoz N Soria D Galiana L Bertolaccini, et al. 2007 Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases Medicine (Baltimore) 86 242 251 10.1097/MD. 0b013e3181441a68 (Pubitemid 47067483)
18. Guignard S, Gossec L, Bandinelli F, Dougados M. Comparison of the clinical characteristics of vasculitis occurring during anti-tumor necrosis factor treatment or not in rheumatoid arthritis patients. A systematic review of 2707 patients, 18 vasculitis. Clin Exp Rheumatol. 26(3) Suppl 49:S23-9.
19. N Nishimoto N Miyasaka K Yamamoto S Kawai T Takeuchi J Azuma, et al. 2009 Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy Mod Rheumatol 19 12 19 1:CAS:528: DC%2BD1MXhsFKmsLk%3D 18979150 10.1007/s10165-008-0125-1
20. B Liang DB Gardner DE Griswold PJ Bugelski XY Song 2006 Anti-interleukin-6 monoclonal antibody inhibits autoimmune responses in a murine model of systemic lupus erythematosus Immunology 119 296 305 1:CAS:528:DC%2BD28XhtF2rsrbO 17067309 10.1111/j.1365-2567.2006.02433.x (Pubitemid 44571047)